MedTrace Logo

Human Infection Study of H3N2 Influenza in Healthy Adults

NCT06972810 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2026-04-30

No results posted yet for this study

Summary

This study will examine how the immune system responds to a flu virus (H3N2) during and after infection in health adults aged between 18 and 50 while in an inpatient facility.

The study uses a specific flu virus called the H3N2 influenza challenge virus, that was produced specifically for use in clinical research in controlled conditions. From a previous study, mild to moderate symptoms are expected.

This is the first time that a flu challenge study has been undertaken in Australia.

Conditions

Interventions

OTHER

A/Texas/71/2017, clade 3C3a H3N2 influenza virus

The intervention product is a live challenge virus that is manufactured in the USA under Good Manufacturing Practice (GMP). The challenge will be administered intranasally using a sprayer device. Participants will be admitted into an inpatient facility prior to the administration of the flu virus. Following inoculation, they will be quarantined for a minimum of 8 days prior to discharge. Participants will receive supportive care and PCR positive participants will receive an effective antiviral medication. Participants will be followed for a total of 6 months.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • WHO Collaborating Centre for Reference and Research on Influenza

    collaborator UNKNOWN

  • University of Melbourne

    lead OTHER

Principal Investigators

  • Dr Gail Cross, MBSS (BSc), FRACP · University of Melbourne

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2025-11-26
Completion
2025-11-26

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06972810 on ClinicalTrials.gov